Mitochondrial protein interaction landscape of SS-31.
Juan D ChavezXiaoting TangMatthew D CampbellGustavo ReyesPhilip A KramerRudy StuppardAndrew KellerHuiliang ZhangPeter S RabinovitchDavid J MarcinekJames E BrucePublished in: Proceedings of the National Academy of Sciences of the United States of America (2020)
Mitochondrial dysfunction underlies the etiology of a broad spectrum of diseases including heart disease, cancer, neurodegenerative diseases, and the general aging process. Therapeutics that restore healthy mitochondrial function hold promise for treatment of these conditions. The synthetic tetrapeptide, elamipretide (SS-31), improves mitochondrial function, but mechanistic details of its pharmacological effects are unknown. Reportedly, SS-31 primarily interacts with the phospholipid cardiolipin in the inner mitochondrial membrane. Here we utilize chemical cross-linking with mass spectrometry to identify protein interactors of SS-31 in mitochondria. The SS-31-interacting proteins, all known cardiolipin binders, fall into two groups, those involved in ATP production through the oxidative phosphorylation pathway and those involved in 2-oxoglutarate metabolic processes. Residues cross-linked with SS-31 reveal binding regions that in many cases, are proximal to cardiolipin-protein interacting regions. These results offer a glimpse of the protein interaction landscape of SS-31 and provide mechanistic insight relevant to SS-31 mitochondrial therapy.
Keyphrases
- oxidative stress
- mass spectrometry
- binding protein
- protein protein
- amino acid
- stem cells
- pulmonary hypertension
- protein kinase
- high resolution
- gene expression
- genome wide
- machine learning
- cell death
- dna methylation
- artificial intelligence
- young adults
- big data
- papillary thyroid
- reactive oxygen species
- replacement therapy
- simultaneous determination